Safety evaluation of repeated intravitreal injections of bevacizumab and ranibizumab in rabbit eyes

Retina

Volumn 30, Issue 4, 2010, Pages 671-681

  Zayit Soudry, Shiri ^a   Zemel, Esther ^b   Loewenstein, Anat ^a   Perlman, Ido ^b  

^a TEL AVIV UNIVERSITY   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Bevacizumab; Electroretinography; Rabbit; Ranibizumab; Repeated injections; Retinal toxicity; VEP

Indexed keywords

BEVACIZUMAB; GLIAL FIBRILLARY ACIDIC PROTEIN; RANIBIZUMAB; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CONTROLLED STUDY; DRUG SAFETY; ELECTRORETINOGRAPHY; EVOKED VISUAL RESPONSE; EYE; EYE TOXICITY; FOLLOW UP; HISTOPATHOLOGY; IMMUNOCYTOCHEMISTRY; IMMUNOREACTIVITY; MORPHOLOGY; MULTIPLE CYCLE TREATMENT; NONHUMAN; RABBIT; RETINA; STAINING;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; DARK ADAPTATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; EVOKED POTENTIALS, VISUAL; EYE; GENE EXPRESSION REGULATION; GLIAL FIBRILLARY ACIDIC PROTEIN; RABBITS;

EID: 77951180932     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3181c0858c     Document Type: Article

References (62)

1. Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin) a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 2005;333:328-335.
2. Lopez PF, Sippy BD, Lambert HM, Thach AB, Hinton DR. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age related macular degeneration related choroidal neovascular membranes. Invest Ophthalmol Vis Sci 1996;37: 855-868.
3. Frank RN, Amin RH, Eliott D, Puklin JE, Abrams GW. Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranes. Am J Ophthalmol 1992;122:393-403.
4. Kvanta A, Algvere PV, Berglin L, Seregard S. Subfoveal fibrovascular membranes in age related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci 1996;37:1929-1934.
5. Kliffen M, Sharma HS, Mooy CM, Kerkvliet S, de Jong PT. Increased expression of angiogenic growth factors in age related maculopathy. Br J Ophthalmol 1997;81:154-162.
6. Rakic JM, Lambert V, Devy L, et al. Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. Invest Ophthalmol Vis Sci 2003;44:3186-3993.
7. Adamis AP, Miller JW, Bernal MT, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994;118: 445-450.
8. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331: 1480-1487.
9. Malecaze F, Clamens S, Simorre-Pinatel V, et al. Detection of vascular endothelial growth factor messenger RNA and vascular endothelial growth factor- like activity in proliferative diabetic retinopathy. Arch Ophthalmol 1994;112:1476-1482.
10. Ferrara N, Damico L, Shams N, Lowman H, Kim R. Development of ranibizumab, an anti-vascular endothelial growth factor antigen-binding fragment, as therapy for neovascular age related macular degeneration. Retina 2006;26:859-870.
11. Rosenfeld PJ, Brown DM, Heier DS, et al; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431.
12. Brown DM, Kaiser PK, Michels M, et al; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular agerelated macular degeneration. N Engl J Med 2006;355:1432-1444.
13. Regillo CD, Brown DM, Abraham P, et al; PIER Study Group. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1. Am J Ophthalmol 2008;145:239-248.
14. Luthra S, Narayanan R, Marques LE, et al. Evaluation of in vitro effects of bevacizumab (Avastin) on retinal pigment epithelial, neurosensory retinal, and microvascular endothelial cells. Retina 2006;26:512-518.
15. Spitzer MS, Wallenfels-Thilo B, Sierra A, et al. Antiproliferative and cytotoxic properties of bevcizumab on different ocular cells. Br J Ophthalmol 2006;90:1316-1321.
16. Spitzer MS, Yoeruek E, Sierra A, et al. Comparative antiproliferative and cytotoxic profile of bevacizumab (Avastin), pegaptanib (Macugen) and ranibizumab (Lucentis) on different ocular cells. Graefes Arch Clin Exp Ophthalmol 2007;245: 1837-1842.
17. Iriyama A, Chen YN, Tamaki Y, Yanagi Y. Effect of anti- VEGF antibody on retinal ganglion cells in rats. Br J Ophthalmol 2007;91:1230-1233.
18. Inan UU, Avci B, Kusbeci T, Kaderli B, Avci R, Temel SG. Preclinical safety evaluation of intravitreal injection of fulllength humanized vascular endothelial growth factor antibody in rabbit eyes. Invest Ophthalmol Vis Sci 2007;48:1773-1781.
19. Feiner L, Barr EE, Shui YB, Holekamp NM, Brantley MA Jr. Safety of intravitreal injection of bevacizumab in rabbit eyes. Retina 2006;26:882-888.
20. Bakri SJ, Cameron JD, McCannel CA, Pulido JS, Marler JD. Absence of histologic retinal toxicity of intravitreal bevacizumab in a rabbit model. Am J Ophthalmol 2006;14:162-164.
21. Shahar J, Avery RL, Heilweil G, et al. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina 2006;26:262-269.
22. Rosenfeld PJ, Schwartz SD, Blumenkranz MS, et al. Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology 2005;112:1048-1053.
23. Ziemssen F, Luke M, Messias A, et al; Tuebingen Bevacizumab Study Group. Safety monitoring in bevacizumab (Avastin) treatment: retinal function assessed by psychophysical (visual fields, colour vision) and electrophysiological (ERG/EOG) tests in two subgroups of patients. Int Ophthalmol 2008;28:101-109.
24. Maturi RK, Bleau L, Wilson DL. Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment. Retina 2006;26:270-274.
25. Manzano RPA, Peyman GA, Khan P, Kivilcim M. Testing intravitreal toxicity of bevacizumab (Avastin). Retina 2006; 26:257-261.
26. Husain D, Kim I, Gauthier D, et al. Safety and efficacy of intravitreal injection of ranibizumab in combination with verteporfin PDT on experimental choroidal neovascularization in the monkey. Arch Ophthalmol 2005;123:509-516.
27. Wickremasinghe SS, Michalova K, Gilhotra J, et al. Acute intraocular inflammation after intravitreous injections of bevacizumab for treatment of neovascular age-related macular degeneration. Ophthalmology 2008;115:1911-1915.
28. Georgopoulos M, Polak K, Prager F, Prünte C, Schmidt- Erfurth U. Characteristics of severe intraocular inflammation following intravitreal injection of bevacizumab (Avastin® ). Br J Ophthalmol 2009;93:457-462.
29. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004;25:581-611. (Pubitemid 39099316)
30. Alon T, Hemo I, Itin A, Pe'er J, Stone J, Keshet E. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1995;1:1024-1028.
31. Nishijima K, Ng YS, Bradley J, et al. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol 2007;171:53-67.
32. Stahl A, Feltgen N, Fuchs A, Bach M. Electrophysiological evaluation of retinal photoreceptor function after repeated bevacizumab injections. Doc Ophthalmol 2009;118:81-88.
33. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007;114:855-859.
34. Goldstein M, Zemel E, Loewenstein A, Perlman I. Retinal toxicity of indocyanine green in albino rabbits. Invest Ophthalmol Vis Sci 2006;47:2100-2107.
35. Avastin: Scientific Discussion. Available at: www.emea. europa.eu/humandocs/Humans/EPAR/avastin/avastin.htm. Accessed February 12, 2009.
36. Holford NHG, Benet LZ. Pharamacokinetics and pharmacodynamics: rationale dose selection and the time course of drug action. In: Katzung BG, ed. Basic and Clinical Pharmacology. Norwalk, CT: Lange; 1995:33-47.
37. Lucentis:ScientificDiscussion.Availableat:www.emea.europa. eu/humandocs/Humans/EPAR/lucentis/lucentis.htm. Accessed February 12, 2009.
38. Gaudreault J, Fei D, Rusit J, Suboc P, Shiu V. Preclinical pharmacokinetics of ranibizumab (rhufabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci 2005; 46:726-733.
39. Hood DC, Birch DG. A computation model of the amplitude and implicit time of the b-wave on the human ERG. Vis Neurosci 1992;8:107-126.
40. Fulton AB, Rushton WAH. The human rod ERG: correlation with psychophysical responses in light and dark adaptation. Vision Res 1978;18:793-800.
41. Robson JG, Frishman LJ. Response linearity and kinetics of the cat retina: the bipolar cell component of the dark-adapted electroretinogram. Vis Neurosci 1995;12:837-850.
42. Ripps H, Witkovsky P. Neuron-glia interaction in the brain and retina. In: Osborne NV, Chandler GJ, eds. Progress in Retinal Research. Vol 4. New York, NY: Pergamon Press; 1985:181-219.
43. Karwoski CJ, Xu X. Current source-density analysis of lightevoked field potentials in rabbit retina. Vis Neurosci 1999;16: 369-377.
44. Lei B, Perlman I. The contribution of voltage- and timedependent potassium conductance to the electroretinogram in rabbits. Vis Neurosci 1999;16:743-754.
45. Perlman I. Relationship between the amplitudes of the b wave and a wave as a useful index for evaluating the electroretinogram. Br J Ophthalmol 1983;67:443-448.
46. Nork TM, Ghobrial MW, Peyman GA, Tso MO. Massive retinal gliosis. A reactive proliferation of Muller cells. Arch Ophthalmol 1986;104:1383-1389.
47. Penn JS, Thum LA, Rhem MN, Dell SJ. Effects of oxygen rearing on the electroretinogram and GFA-protein in the rat. Invest Ophthalmol Vis Sci 1988;29:1623-1630.
48. Ekstrom P, Sanyal S, Narfstrom K, Chader GJ, van Veen T. Accumulation of glial fibrillary acidic protein in Muller radial glia during retinal degeneration. Invest Ophthalmol Vis Sci 1988;29:1363-1371.
49. Li Q, Zemel E, Miller B, Perlman I. Early retinal damage in experimental diabetes: electroretinographical and morphological observations. Exp Eye Res 2002;74:615-625.
50. Gerber HP, Dixit V, Ferrara N. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J Biol Chem 1998;273: 13313-13316. (Pubitemid 28246905)
51. Gerber HP, McMurtrey A, Kowalski J, et al. VEGF regulates endothelial cell survival by the PI3-kinase/Akt signal transduction pathway, requirement for Flk-1/KDR activation. J Biol Chem 1998;273:30336-30343.
52. Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 1999;103:159-165.
53. Guerrin M, Moukadiri H, Chollet P, et al. Vasculotropin/ vascular endothelial growth factor is an autocrine growth factor for human retinal pigment epithelial cells cultured in vitro. J Cell Physiol 1995;164:385-394.
54. Yang R, Thomas GR, Bunting S, et al. Effects of vascular endothelial growth factor on the hemodynamics and the cardiac performance. J Cardiovasc Pharmacol 1996;27:838-844.
55. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-VEGF antibody, for metastatic renal cancer. N Engl J Med 2003;349:427-434.
56. Storkebaum E, Lambrechts D, Carmeliet P. VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection. Bioessays 2004;26:943-954.
57. Oosthuyse B, Moons L, Storkebaum E, et al. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet 2001;28:131-138.
58. Lambrechts D, Storkebaum E, Morimoto M, et al. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet 2003;34:383-394.
59. Lambrechts D, Storkebaum E, Carmeliet P. VEGF: necessary to prevent motoneuron degeneration, sufficient to treat ALS? Trends Mol Med 2004;10:275-282.
60. Breen EC. VEGF in biological control. J Cell Biochem 2007; 102:1358-1367.
61. Ueno S, Pease ME, Wersinger DM, et al. Prolonged blockade of VEGF family members does not cause identifiable damage to retinal neurons or vessels. J Cell Physiol 2008;217:13-22.
62. Zemel E, Loewenstein A, Lazar M, Perlman I. Ocular pigmentation protects the rabbit retina from gentamicin-induced toxicity. Invest Ophthalmol Vis Sci 1995;36:1875-1884